ArticleFrontiers in cellular and infection microbiology2017
Risk Factors, Clinical Presentation, and Outcome of
Article in Frontiers in cellular and infection microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 109 citations in OpenAlex.
- Integrating machine learning and artificial intelligence in the management of Acinetobacter infections: a narrative review.Infection · 2026Review
- OmpA virulence factor, a promising conserved vaccine candidate against Acinetobacter baumannii, could trigger autoreactive immune responses in susceptible population.BMC immunology · 2025Article
- Comparative genomics of Acinetobacter baumannii from Egyptian healthcare settings reveals high-risk clones and resistance gene mobilization.BMC infectious diseases · 2025Article
- Predicting infections with multidrug-resistant organisms (MDROs) in neurocritical care patients with hospital-acquired pneumonia (HAP): development of a novel multivariate prediction model.Microbiology spectrum · 2025Article
- Exploring the impact of comorbidities and drug resistance on mortality in ICU-acquired bloodstream infections.AMB Express · 2025Article
- Analyzing Clinical Parameters and Bacterial Profiles to Uncover the COPD Exacerbations: A Focus on Intensive Care Unit Challenges.Medicina (Kaunas, Lithuania) · 2025Article
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- Regulation of antibiotic persistence and pathogenesis in Acinetobacter baumannii by glutamate and histidine metabolic pathways.BMC microbiology · 2025Article
- Antibiotic resistance in the Middle East and Southern Asia: a systematic review and meta-analysis.JAC-antimicrobial resistance · 2025Review
- Risk and Prognostic Factors for Bloodstream Infections Due to Clonally TransmittedInfection and drug resistance · 2025Article
- Insertion Sequences within Oxacillinases Genes as Molecular Determinants ofMicroorganisms · 2024Article
- Seasonal meropenem resistance in Acinetobacter baumannii and influence of temperature-driven adaptation.BMC microbiology · 2024Article
- A retrospective analysis of carbapenem-resistantJournal of intensive medicine · 2024Article
- Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistantMicrobiology spectrum · 2024Article
- Corticosteroid Dosing Level, Incidence and Profile of Bacterial Blood Stream Infections in Hospitalized COVID-19 Patients.Viruses · 2024Article
- Retrospective analysis of Acinetobacter baumannii bacteraemia risk factors, complications and mortality in a tertiary university hospital in Saudi Arabia.Access microbiology · 2024Article
- Risk factors and predictive model for nosocomial infections by extensively drug-resistantFrontiers in cellular and infection microbiology · 2024Article
- Cefiderocol and Sulbactam-Durlobactam against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon.Antimicrobial resistance and infection control · 2023Observational
- Does Emerging Carbapenem Resistance inInfectious disease reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.